Abstracts tagged "Atherosclerosis"

Abstract Number: 1267 • 2013 ACR/ARHP Annual Meeting
Impact Of Disease Duration On Vascular Surrogates Of Early Atherosclerosis In Childhood-Onset Systemic Lupus Erythematosus
Julie Barsalou¹, Timothy J. Bradley², Cameron Slorach², Lawrence W.K. Ng³, Deborah M. Levy⁴ and Earl D. Silverman¹, ¹Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
Background/Purpose: Cardiovascular disease is a leading cause of morbidity and mortality in adults with systemic lupus erythematosus. Exposure to atherogenic risk factors in childhood-onset SLE…
Abstract Number: 1210 • 2013 ACR/ARHP Annual Meeting
Epicardial Adipose Tissue and Atherosclerosis In Patients With Familial Mediterranean Fever
Adem Kucuk¹, Yalcin Solak², Hakan Akilli³, Oguzhan Yildirim³, Ibrahim Guler⁴, Ramazan Ucar⁵, Alpay Aribas³, Orhan Ozbek⁶, Mehmet Kayrak³ and Recep Tunc¹, ¹Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, ²Karaman State Hospital, Division of Nephrology, Karaman, Turkey, ³Necmettin Erbakan University, Division of Cardiology, Konya, Turkey, ⁴Konya Research and Education Hospital, Division of Radiology, Konya, Turkey, ⁵Konya Education and Research Hospital, Department ofInternal Medicine, Konya, Turkey, ⁶Necmettin Erbakan University, Division of Radiology, Konya, Turkey
Background/Purpose : Familial Mediterranean Fever (FMF) is a chronic autosomal recessive hereditary disease characterized by episodic attacks of fever and inflammation of serosal and synovial…
Abstract Number: 1157 • 2013 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase Inhibition Prevents Neutrophil Extracellular Trap Formation, Modulates Innate Immune Responses, and Reduces Vascular Damage In Mice
Jason S. Knight¹, Wei Luo², Alexander A. O'Dell¹, Wenpu Zhao³, Venkataraman Subramanian⁴, Chiao Guo², Robert C. Grenn³, Paul Ryan Thompson⁴, Daniel T. Eitzman² and Mariana J. Kaplan⁵, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Cardiology, Ann Arbor, MI, ³University of Michigan Rheumatology, Ann Arbor, MI, ⁴The Scripps Research Institute, Jupiter, FL, ⁵Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Neutrophil extracellular trap (NET) formation promotes vascular damage, while stimulating interferon alpha (IFN-α) production in diseased arteries. Patients with rheumatoid arthritis and systemic…
Abstract Number: 887 • 2013 ACR/ARHP Annual Meeting
Atherosclerosis and Cardiovascular Disease In Systemic Lupus Eryhematosus Are Related To An Inflammatory/Oxidative Status Linked To The Autoimmune Condition and The Clinical Activity Of The Disease. Effect Of Statins Treatment
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon¹, Carlos Perez-Sanchez¹, Mª Angeles Aguirre², Nuria Barbarroja¹, Tomás Cerdó-Ráez³, Maria Laura Bertolaccini⁴, Munther A. Khamashta⁵, Antonio Rodriguez-Ariza⁶, Yolanda Almaden⁷, Husam Khraiwesh⁸, Jose Antonio Gonzalez-Reyes⁹, Jose Manuel Villalba¹⁰, Eduardo Collantes¹¹ and Mª Jose Cuadrado¹², ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ³Imibic, Córdoba, Spain, ⁴Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ⁶Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁷Imibic, Códoba, Spain, ⁸UCO, Córdoba, Spain, ⁹Cell Biology, Physiology and Immunology, University of Cordoba, Cordoba, Spain, ¹⁰Cell Biology, Physiology and Immunology, University of Cordoba, Agrifood Campus of International Excelence (ciA3), Cordoba, Spain, ¹¹Rheumatology, Hospital Reina Sofia, Cordoba, Spain, ¹²Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: Atherosclerosis (AT) and cardiovascular disease (CVD) are enhanced systemic lupus erythematosus (SLE). Although there is evidence that statins have anti-inflammatory properties, their mechanism of…
Abstract Number: 763 • 2013 ACR/ARHP Annual Meeting
The Risk Of Myocardial Infarction In Systemic Sclerosis: A Population-Based Cohort Study
Iman Hemmati¹, Hyon K. Choi^2,3, Kamran Shojania^3,4, Eric C. Sayre³ and J. Antonio Avina-Zubieta^3,5, ¹Deparment of Medicine and Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: An increased risk of premature atherosclerosis has been well described in patients with rheumatoid arthritis and systemic lupus erythematosus. However, there is limited data…
Abstract Number: 559 • 2013 ACR/ARHP Annual Meeting
Effects Of In Vivo Treatment With Hydroxychloroquine On Endothelial Function In a Murine Model Of Systemic Lupus Erythematosus
Marta Mosca¹, Chiara Tani², Sabrina Vagnani³, Linda Carli^3,4, Rosaria Talarico⁵, Chiara Baldini⁵, Stefano Bombardieri³ and Agostino Virdis⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴GenOMeC PhD, University of Siena, Siena, Italy, ⁵University of Pisa, Rheumatology Unit, Pisa, Italy, ⁶Department of Clinical and Experimental Medicine. University of Pisa, Hypertension Unit, University of Pisa, Pisa, Italy
Background/Purpose: Antimalarial drugs are a cornerstone of treatment of systemic lupus erythematosus (SLE). It has been suggested that antimalarial drugs may have a protective effect…
Abstract Number: 2898 • 2013 ACR/ARHP Annual Meeting
Atherosclerosis In Systemic Lupus Erythematosus (SLE) and Controls, -An Analysis Of SLE Subgroups
Johanna Gustafsson¹, Kerstin Jensen-Urstad², Marie Herlitz-Lindberg², Sonia Möller¹, Susanne Pettersson¹, Iva Gunnarsson¹, Anders Larsson³ and Elisabet Svenungsson⁴, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Department of Clinical Physiology, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Chemistry and Pharmacology, Akademiska Hospital, Uppsala, Sweden, ⁴Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Atherosclerosis is often assumed to be the main underlying cause of premature vascular events (VE) among patients with systemic lupus erythematosus (SLE) and accelerated…
Abstract Number: 469 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study
Jaime Calvo-Alén¹, Carmela Baamonde², Ignacio Villa¹, Víctor Martínez-Taboada³, Mario Agudo⁴ and Juan Gómez-Gerique⁵, ¹Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, ²Biochemistry, Hospital Universitario Sierrallana, Torrelavega, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Anti-TNF therapy induces elevations in total cholesterol levels although does not seem to modify the atherogenic index. Otherwise, it appears to have a cardiovascular…
Abstract Number: 1252 • 2012 ACR/ARHP Annual Meeting
Association of Paraoxonase 1 Gene Polymorphisms and Enzyme Activity with Carotid Plaque in Rheumatoid Arthritis
Christina Charles-Schoeman¹, Yuen Yin Lee¹, Veena K. Ranganath¹, John FitzGerald¹, Mihaela B. Taylor², Maureen A. McMahon¹, David Elashoff³ and Srinivasa T. Reddy⁴, ¹University of California, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles, CA, ³Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁴Medicine-Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Paraoxonase 1 (PON1) is a high density lipoprotein (HDL) associated enzyme, which promotes the anti-oxidant and anti-inflammatory properties of HDL. PON1 polymorphisms and enzyme…
Abstract Number: 1253 • 2012 ACR/ARHP Annual Meeting
Identifying Vulnerable Plaque in Rheumatoid Arthritis: A Pilot Study Using Novel Microbubble-Contrast Enhanced Carotid Ultrasonography
Kimberly P. Liang¹, Douglas P. Landsittel², Suresh R. Mulukutla³, Steven E. Reis⁴, Marc C. Levesque¹, Flordeliza S. Villanueva³, Hunter C. Champion⁵ and Larry W. Moreland¹, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Biostatistics and Clinical and Translational Science, University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, ³Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Cardiology and Department of Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is independently associated with a higher risk of cardiovascular disease (CVD). Markers of systemic inflammation, as seen in RA, are associated…
Abstract Number: 1255 • 2012 ACR/ARHP Annual Meeting
Vascular Calcification On Hand and Feet X-Rays, VFA Imaging of the Spine, and Cardiovascular Disease in Rheumatoid Arthritis
Ausaf Mohammad¹, Collette English², Derek Lohan², Diane Bergin², Sarah Mooney², John Newell³, Martin O'Donnell⁴, Robert J. Coughlan¹ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Radiology, Galway University Hospitals, Galway, Ireland, ³Clinical Research Facility, National University of Ireland, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Vascular Calcification on Hand and Feet X-rays, VFA imaging of the spine, and Cardiovascular Disease in Rheumatoid ArthritisBackground/Purpose: Patients with rheumatoid arthritis (RA) are at…
Abstract Number: 1205 • 2012 ACR/ARHP Annual Meeting
Study of Association of CD40-CD154 Gene Polymorphisms with Disease Susceptibility and Cardiovascular Risk in Spanish Rheumatoid Arthritis Patients
Mercedes García-Bermúdez¹, Carlos González-Juanatey², Alfonso Corrales³, Raquel López-Mejías⁴, Maria Teruel⁵, Jose A. Miranda-Filloy⁶, Santos Castañeda-Sanz⁷, Alejandro Balsa⁸, B. Fernández-Gutierrez⁹, Isidoro González-Álvaro¹⁰, Carmen Gómez-Vaquero¹¹, R. Blanco Alonso¹², Javier Llorca¹³, Javier Martin¹⁴ and Miguel Angel González-Gay⁴, ¹Immunology and Cellular Biology, Instituto de Parasitologia y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ²Cardiology Division, Hospital Lucus Augusti, Lugo, Spain, ³Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ⁶Rheumatology, Division of Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. Madrid. Spain, Madrid, Spain, ⁸Rheumatology, La Paz Hospital. IdiPaz, Madrid, Spain, ⁹Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ¹⁰Servicio de Reumatología, Reumatología (Hospital Universitario de La Princesa), Madrid, Spain, ¹¹Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ¹²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹³Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ¹⁴Immunology, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased cardiovascular (CV) mortality. Since CD40-CD154 binding has direct consequences on inflammation process initiation,…
Abstract Number: 2272 • 2012 ACR/ARHP Annual Meeting
Gene Expression Signatures in Monocytes From Primary Antiphospholipd Syndrome, Systemic Lupus Erythematosus and Lupus with Antiphospholipid Syndrome Identify Specific Pathways Involved in the Pathogenesis of Atherosclerosis and Cardiovascular Disease
Chary Lopez-Pedrera¹, Sebastiano Messineo², Carlos Perez-Sanchez¹, Patricia Ruiz-Limon¹, Mª Angeles Aguirre³, Rosario M. Carretero-Prieto⁴, Antonio Rodriguez-Ariza¹, Nuria Barbarroja⁴, Francisco Velasco¹, Munther A. Khamashta⁵, Eduardo Collantes-Estevez¹ and Mª Jose Cuadrado⁶, ¹IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ²Dipartimento di Scienze della Salute, Universitá Magna Graecia di Catanzaro, Dipartimento di Scienze della Salute, Universitá Magna Graecia di Catanzaro, Italy., Catanzaro, Italy, ³Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ⁵Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ⁶Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by immune-mediated inflammation in multiple organ systems. SLE, primary Antiphospholipid syndrome (APS) and secondary APS (SAPS) share several…
Abstract Number: 1211 • 2012 ACR/ARHP Annual Meeting
ANTI-Cyclic Citrullinated Protein Antibodies Induce Inflammation and Oxidative Stress in WHITE Blood CELLS of Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Carlos Perez-Sanchez¹, Patricia Ruiz-Limon¹, Mª Angeles Aguirre², Rosario M. Carretero-Prieto¹, Antonio Rodriguez-Ariza³, Nuria Barbarroja¹, Pilar Font¹, Francisco Martinez², Inmaculada Gomez-Gracia², Mª Jose Cuadrado⁴ and Eduardo Collantes-Estevez², ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: Anti-cyclic citrulinated protein antibodies (anti-CCP) are the most specific autoantibody markers in rheumatoid arthritis (RA) patients. However no previous studies have evaluated their role…
Abstract Number: 2078 • 2012 ACR/ARHP Annual Meeting
Low-Density Lipoprotein Receptor Deficiency Ameliorates the Development of Inflammatory Arthritis
Shawn Rose¹ and Harris R. Perlman², ¹Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) carry a higher risk of cardiovascular disease compared to the general population. The low-density lipoprotein receptor (LDLR) and Apolipoprotein…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.